Kit-like 18 F-labeling of an Estradiol Derivative As a Potential PET Imaging Agent for Estrogen Receptor-Positive Breast Cancer

16α-18F-fluoroestradiol (18F-FES) has been developed as a promising positron emission tomography (PET) imaging agent for targeting estrogen receptor positive (ER+) breast cancer in the clinical trial. However, the radiosynthesis of 18F-FES often requires two steps and tough experimental conditions. Therefore, a new estradiol derivative (18F-AmBF3-ES) was prepared by an efficient one-step 18F-radiolabeling method. The tracer was obtained in high yield (~65%) and excellent radiochemical purity (>98%) within 30 min. The uptake rate of 18F-AmBF3-ES in ER+ cells was about 3.5% at 30 min. The results suggested that the tracer may be a potential PET imaging agent for ER+ breast cancer.